Hydrocephalus is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain that causes increased intracranial pressure (ICP) that can lead to brain damage and death. The standard of care for these patients is to implant a shunt, like implantable pressure-controlled plumbing, that  re-routes the excess CSF from the inside of the brain to the peritoneal cavity (abdomen) where it is absorbed safely. The number one cause of shunt implant failure is occlusion of the proximal catheter in the ventricles of the brain from blood, debris, or tissue. The ReFlow implant, when added to any shunt implant, allows for selective, non-invasive flushing of the proximal catheter to maintain or re-establish CSF flow in the implanted shunt to potentially avoid repeat brain surgeries needed to replace the occluded shunt components. 

Hydrocephalus is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain that causes increased intracranial pressure (ICP) that can lead to brain damage and death. The standard of care for these patients is to implant a shunt, like implantable pressure-controlled plumbing, that  re-routes the excess CSF from the inside of the brain to the peritoneal cavity (abdomen) where it is absorbed safely. The number one cause of shunt implant failure is occlusion of the proximal catheter in the ventricles of the brain from blood, debris, or tissue. The ReFlow implant, when added to any shunt implant, allows for selective, non-invasive flushing of the proximal catheter to maintain or re-establish CSF flow in the implanted shunt to potentially avoid repeat brain surgeries needed to replace the occluded shunt components. 

Through the accelerator, Anuncia Medical has been able to better identify and enact our clinical and sales strategy as we embark into commercialization of our ReFlow Mini. The ability to leverage Mayo Clinic and ASU resources to obtain much needed clinical and technical feedback for the development of our product pipeline is immensely beneficial. This is a game changing experience for start-up companies who otherwise wouldn’t have access to these world-class subject matter experts (SMEs).

"Beyond the valuable connections to the Mayo Clinic’s and ASU’s word-class clinicians and subject matter experts, the accelerator has given us the ability to closely interact with 8 other amazing, synergistic, healthcare start-up companies from around the globe, many of which we hope to collaborate with well beyond our intense 2-week time together. "

Elsa Chi Abruzzo
CEO and President